ClinicalTrials.gg
CompletedNCT01078675Updated Apr 7, 2015Results posted

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

A Phase 3 interventional study of rosuvastatin calcium and rosuvastatin calcium in Familial Hypercholesterolaemia, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-04-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.

Enrollment
8th of 33
315 · median 153
Started
2010
the only one that year
Phase 3
14 of 35
3 open now
Registered
12th of 35
by date
Lead sponsor
2 of 35
AstraZeneca

Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2010, is one of 14 in phase 3, and was the 12th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, or all of them as a file.
02

Study summary

This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability and efficacy of the study medication in these patients.

This study will also measure levels of drug in the blood and see how well it is tolerated. This is known as pharmacokinetic (PK) analysis.

At baseline only a small number of patients will participate in a single dose PK phase over 24 hours.

In order to see if this medication works, a control group of healthy siblings will help the researchers to compare certain results.

03

Conditions studied

  • Familial Hypercholesterolaemia

Keywords

  • Familial Hypercholesterolaemia
  • pediatric
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children and adolescents (aged 6 to less than 18 years) with Familial Hypercholesterolaemia
  • Patients aged between 6 and less than 10 years of age must not be taking a statin medicine

Exclusion criteria

Exclusion Criteria:

  • History of muscle or sensitivity reactions to any statin medicines
  • Current active liver disease or dysfunction (except a confirmed diagnosis of Gilbert's disease)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    1

    Drug: rosuvastatin calcium

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C

    Negative values represent a decrease and positive values represent an increase. In total, 198 patients were treated. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: At Month 3, Month 12 and Month 24

  2. Sexual Maturation by Tanner Staging at Baseline

    Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

    Time frame: At Baseline

  3. Single Dose PK - Cmax

    Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

    Time frame: Serial blood samples over 24 hours.

  4. Percent Change From Baseline in Height

    One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: At Month 12 and Month 24

  5. Sexual Maturation by Tanner Staging at Month 12

    Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

    Time frame: At Baseline

  6. Sexual Maturation by Tanner Staging at Month 24

    Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

    Time frame: At Baseline

  7. Single Dose PK - Tmax

    Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

    Time frame: Serial blood samples over 24 hours

  8. Single Dose PK - AUC(0-24)

    Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

    Time frame: Serial blood samples over 24 hours

Secondary outcomes

  1. Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1

    One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: At Month 3, Month 12 and Month 24

  2. Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)

    One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: At Month 12 and Month 24

  3. Adverse Events

    Number of participants with Various Categories of AE's. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: 2-year study period

  4. Total Duration of Exposure

    Total duration of exposure was calculated as \[last dose date of rosuva - first dose date of rosuva + 1 day\]. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: 2-year study period

  5. Overal Treatment Adherence

    Overall adherence rate was calculated as the weighted mean of adherence rates of all consecutive visits after baseline, in which the adherence rate between 2 consecutive visits was a percentage of the number of rosuvastatin taken divided by duration of exposure. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

    Time frame: 2-year study period

07

Results

Posted Feb 2, 2015

Participant flow

250 patients with FH were screened. Additionally, 65 healthy siblings (HS) were enrolled. HS refers to healthy subjects that were siblings of either the study participants or other paediatric patients with HeFH that were not participating in the study. HS were enrolled to have assessments of cIMT, but did not participate further.

Participant flow — Overall Study
MilestoneRosuvastatinHealthy Siblings
Started25065
Patients treated1980
Completed18259
Not completed686
Withdrew: Withdrawal by subject73
Withdrew: Protocol violation560
Withdrew: Provided in crf for specific reasons23
Withdrew: Adverse event30

Outcome measures

PrimaryPercent Change From Baseline in LDL-C

Negative values represent a decrease and positive values represent an increase. In total, 198 patients were treated. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
At Month 3, Month 12 and Month 24
Reported as:
Mean · Percentage change
Percent Change From Baseline in LDL-C
Percentage changeRosuvastatin
LDL-C %Change from Baseline at month 3-37.86 ± 14.392
LDL-C %Change from Baseline at month 12-43.67 ± 14.896
LDL-C %Change from Baseline at month 24-42.88 ± 18.222
Statistical analysis
  • Rosuvastatin · ANCOVA · p = <0.001 (P-value\<0.001 at Month 24. No adjustment for multiple comparisons is made for individual age group.) · Mean difference (final values): -42.88 · -42.88% CI -45.44 to -40.32P-value is two-sided and based on ANCOVA using age group as the fixed factor, and study centre and the baseline value as covariates.
PrimarySexual Maturation by Tanner Staging at Baseline

Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

Time frame:
At Baseline
Reported as:
Number · Participants
Sexual Maturation by Tanner Staging at Baseline
ParticipantsRosuvastatin
Tanner Stage I at Baseline81 ± NA
Tanner Stage II at Baseline32 ± NA
Tanner Stage III at Baseline18 ± NA
Tanner Stage IV at Baseline44 ± NA
Tanner Stage V at Baseline21 ± NA
Not Recorded at Baseline1
PrimarySingle Dose PK - Cmax

Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

Time frame:
Serial blood samples over 24 hours.
Reported as:
Mean · ng/mL
Single Dose PK - Cmax
ng/mLRosuvastatin
Single Dose PK - Cmax3.5717 ± 3.22350
SecondaryPercent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1

One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
At Month 3, Month 12 and Month 24
Reported as:
Mean · Percent change
Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1
Percent changeRosuvastatin
HDL-C %Change from Baseline at Month 35.67 ± 17.445
HDL-C %Change from Baseline at Month 126.35 ± 16.725
HDL-C %Change from Baseline at Month 2411.73 ± 19.996
TC %Change from Baseline at Month 3-29.60 ± 11.433
TC %Change from Baseline at Month 12-33.91 ± 12.050
TC %Change from Baseline at Month 24-32.03 ± 14.530
Triglycerides %Change from Baseline at Month 3-7.95 ± 34.482
Triglycerides %Change from Baseline at Month 12-7.85 ± 37.530
Triglycerides %Change from Baseline at Month 24-0.12 ± 37.682
non-HDL C %Change from Baseline at Month 3-36.35 ± 13.368
non-HDL C %Change from Baseline at Month 12-41.66 ± 14.235
non-HDL C %Change from Baseline at Month 24-40.40 ± 17.555
LDL-C/HDL-C %Change from Baseline at Month 3-39.66 ± 17.381
LDL-C/HDL-C %Change from Baseline at Month 12-45.63 ± 17.082
LDL-C/HDL-C %Change from Baseline at Month 24-46.95 ± 20.126
TC/HDL-C %Change from Baseline at Month 3-31.77 ± 14.874
TC/HDL-C %Change from Baseline at Month 12-36.54 ± 14.474
TC/HDL-C %Change from Baseline at Month 24-37.39 ± 17.079
Trig/HDL-C %Change from Baseline at Month 3-9.05 ± 41.765
Trig/HDL-C %Change from Baseline at Month 12-10.50 ± 40.633
Trig/HDL-C %Change from Baseline at Month 24-7.12 ± 40.585
non-HDL-C/HDL-C %Change from Baseline at Month 3-37.98 ± 17.369
non-HDL-C/HDL-C %Change from Baseline at Month 12-43.71 ± 16.731
non-HDL-C/HDL-C %Change from Baseline at Month 24-44.74 ± 19.896
ApoA-I %Change from Baseline at Month 34.77 ± 14.680
ApoA-I %Change from Baseline at Month 121.41 ± 13.747
ApoA-I %Change from Baseline at Month 242.34 ± 15.027
ApoB %Change from Baseline at Month 3-29.29 ± 12.456
ApoB %Change from Baseline at Month 12-35.65 ± 12.424
ApoB %Change from Baseline at Month 24-35.72 ± 15.710
ApoB/ApoA-I %Change from Baseline at Month 3-31.30 ± 15.524
ApoB/ApoA-I %Change from Baseline at Month 12-35.66 ± 13.920
ApoB/ApoA-I %Change from Baseline at Month 24-35.94 ± 18.743
hsCRP %Change from Baseline at Month 3512.57 ± 4724.249
hsCRP %Change from Baseline at Month 1242.96 ± 226.954
hsCRP %Change from Baseline at Month 2498.36 ± 565.444
SecondaryChange From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)

One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
At Month 12 and Month 24
Reported as:
Mean · mm
Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)
mmRosuvastatinHealthy Siblings
Max cIMT Change from Baseline at Month 120.00626 ± 0.0734460.01707 ± 0.056223
Max cIMT Change from Baseline at Month 240.00189 ± 0.0608640.01202 ± 0.049102
Mean cIMT Change from Baseline at Month 120.00282 ± 0.0411860.01564 ± 0.032052
Mean cIMT Change from Baseline at Month 240.01056 ± 0.0407620.02779 ± 0.031004
SecondaryAdverse Events

Number of participants with Various Categories of AE's. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
2-year study period
Reported as:
Number · Participant
Adverse Events
ParticipantRosuvastatin
Any AE172
AE Leading to Death0
AE Leading to Discontinuation3
Serious AE9
Treatment Related AE29
Treatment Related AE Leading to Death0
Treatment Related AE Leading to Discontinuation3
Treatment Related Serious AE0
SecondaryTotal Duration of Exposure

Total duration of exposure was calculated as \[last dose date of rosuva - first dose date of rosuva + 1 day\]. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
2-year study period
Reported as:
Mean · Days
Total Duration of Exposure
DaysRosuvastatin
Total Duration of Exposure703.5 ± 97.25
PrimaryPercent Change From Baseline in Height

One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
At Month 12 and Month 24
Reported as:
Mean · Percent change
Percent Change From Baseline in Height
Percent changeRosuvastatin
%Change from Baseline at Month 123.20 ± 2.023
%Change from Baseline at Month 245.91 ± 3.968
PrimarySexual Maturation by Tanner Staging at Month 12

Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

Time frame:
At Baseline
Reported as:
Number · Participants
Sexual Maturation by Tanner Staging at Month 12
ParticipantsRosuvastatin
Tanner Stage I at Month 1261 ± NA
Tanner Stage II at Month 1231 ± NA
Tanner Stage III at Month 1221 ± NA
Tanner Stage IV at Month 1232 ± NA
Tanner Stage V at Month 1242 ± NA
Not Recorded at Month 1210
PrimarySexual Maturation by Tanner Staging at Month 24

Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.

Time frame:
At Baseline
Reported as:
Number · Participants
Sexual Maturation by Tanner Staging at Month 24
ParticipantsRosuvastatin
Tanner Stage I at Month 2443 ± NA
Tanner Stage II at Month 2433 ± NA
Tanner Stage III at Month 2423 ± NA
Tanner Stage IV at Month 2432 ± NA
Tanner Stage V at Month 2464 ± NA
Not Recorded at Month 242
PrimarySingle Dose PK - Tmax

Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

Time frame:
Serial blood samples over 24 hours
Reported as:
Mean · hr
Single Dose PK - Tmax
hrRosuvastatin
Single Dose PK - Tmax2.664 ± 1.8851
PrimarySingle Dose PK - AUC(0-24)

Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing

Time frame:
Serial blood samples over 24 hours
Reported as:
Mean · ng*hr/mL
Single Dose PK - AUC(0-24)
ng*hr/mLRosuvastatin
Single Dose PK - AUC(0-24)27.675 ± 26.6417
SecondaryOveral Treatment Adherence

Overall adherence rate was calculated as the weighted mean of adherence rates of all consecutive visits after baseline, in which the adherence rate between 2 consecutive visits was a percentage of the number of rosuvastatin taken divided by duration of exposure. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.

Time frame:
2-year study period
Reported as:
Mean · Percent of doses
Overal Treatment Adherence
Percent of dosesRosuvastatin
Overal Treatment Adherence89.6 ± 12.25

Adverse events

Collected over Treatment Phase. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin—9/197 (4.6%)172/197 (87.3%)
Most frequent serious events
Most frequent serious events
EventRosuvastatin
AppendicitisInfections and infestations1/197
Urinary retention postoperativeInjury, poisoning and procedural complications1/197
Forearm fractureInjury, poisoning and procedural complications1/197
Streptococcal toxic shock syndromeInfections and infestations1/197
Femur fractureInjury, poisoning and procedural complications1/197
Viral pericarditisInfections and infestations1/197
Multiple fracturesInjury, poisoning and procedural complications1/197
Leg fractureInjury, poisoning and procedural complications1/197
EpilepsyNervous system disorders1/197
Pectus carinatumCongenital, familial and genetic disorders1/197
Most frequent other events
Showing 10 of 187
Most frequent other events
EventRosuvastatin
NasopharyngitisInfections and infestations88/197
HeadacheNervous system disorders46/197
InfluenzaInfections and infestations20/197
VomitingGastrointestinal disorders19/197
NauseaGastrointestinal disorders18/197
Gastroenteritis viralInfections and infestations18/197
Influenza like illnessGeneral disorders16/197
Abdominal pain upperGastrointestinal disorders15/197
Abdominal painGastrointestinal disorders13/197
Oropharyngeal painRespiratory, thoracic and mediastinal disorders13/197

Baseline characteristics

Rosuvastatin; All treated patients. Healthy siblings; All patient who started this study

Age, Continuous
Age, Continuous(Years)RosuvastatinHealthy SiblingsTotal
Years11.6 ± 3.3311.5 ± 3.5311.55 ± 3.43
Sex: Female, Male
Sex: Female, Male(Participants)RosuvastatinHealthy SiblingsTotal
Female11032142
Male8833121
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RosuvastatinHealthy SiblingsTotal
Caucasian17853231
non-Caucasian201232
08

Study locations

14 sites
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Leuven, Belgium
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Chicoutimi, Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Groningen, Netherlands
  • Research Site
    Hoorn, Netherlands
  • Research Site
    Leiderdorp, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Waalwijk, Netherlands
  • Research Site
    Oslo, Norway
09

References and documents

Publications

  • Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017 Jul 25;136(4):359-366. doi: 10.1161/CIRCULATIONAHA.116.025158. Epub 2017 Jun 7. PubMed 28592434 ↗
  • Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2014 Jan 17;114(2):307-10. doi: 10.1161/CIRCRESAHA.114.301430. Epub 2013 Nov 5. PubMed 24192652 ↗
  • Tolani S, Pagler TA, Murphy AJ, Bochem AE, Abramowicz S, Welch C, Nagareddy PR, Holleran S, Hovingh GK, Kuivenhoven JA, Tall AR. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis. 2013 Jul;229(1):79-85. doi: 10.1016/j.atherosclerosis.2013.03.031. Epub 2013 Apr 19. PubMed 23684512 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2010
First posted
Mar 2, 2010
Start
Feb 2010
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Feb 2, 2015
Last update
Apr 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01078675
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
Feb 2010
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Feb 2, 2015
Last update
Apr 7, 2015

Study contacts

John J.P. Kastelein, MD, PhD
principal investigator · Chairman, Dept. of Vascular Medicine, Academic Medical Center, Meibergdreef 9

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion